US Q2 earnings growth estimate dips, reflecting Vertex loss, LSEG says

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/16/2026

1. NVDA
2. CRWV
3. SPY
4. BAC
5. BLK
6. RKLB
7. CAT
8. AA
9. MRSH
10. RSG

August 2, 2024 11:07 AM EDT

FILE PHOTO: The New York Stock Exchange is seen February 9, 2011. REUTERS/Eric Thayer/File Photo

By Caroline Valetkevitch

NEW YORK (Reuters) -The earnings growth estimate for S&P 500 companies for the second quarter dipped to 12.9% as of Friday from 13.3% on Thursday, according to LSEG data.

The latest estimate is based on actual results from 376 of the S&P 500 companies and estimates for the rest.

The second-quarter growth estimate was affected by a one-time issue for Vertex Pharmaceuticals, according to Tajinder Dhillon, senior research analyst at LSEG Data & Analytics.

"Otherwise, we would have seen a rise in the overall earnings growth rate to about 13.9%," he said.

Vertex Pharmaceuticals late Thursday reported a second-quarter loss of $12.83 per share, on an adjusted basis, impacted by acquisition related costs for its $4.9 billion deal to buy Alpine Immune Sciences. Analysts were expecting a profit of $4.14 per share.

(Reporting by Caroline ValetkevitchEditing by Nick Zieminski)


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Reuters

Related Entities

Earnings, Definitive Agreement